The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

Feb. 19, 2025 – A vaccine for pregnant women that protects babies from respiratory syncytial virus (RSV) appears safe, according to two new studies that give researchers hope for widespread ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral ...

RSV is a highly contagious seasonal respiratory virus and a ... By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at ...

Respiratory syncytial virus (RSV) is a cold-like illness that can be dangerous for infants, especially those born during the respiratory season. We finally have a tool to protect them, yet ...